• Evaxion announced sustained clinical responses through three years in a phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma.
• No tumor progression occurred during the third year of vaccine-only treatment; vaccine-induced immune responses remained sustained.
• Results will be presented at the ESMO Congress on October 24, 2026, building on two-year findings presented in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230200PRIMZONEFULLFEED1001279409) on October 23, 2026, and is solely responsible for the information contained therein.